0001209191-23-004138.txt : 20230119 0001209191-23-004138.hdr.sgml : 20230119 20230119204226 ACCESSION NUMBER: 0001209191-23-004138 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230117 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marshall Keith W CENTRAL INDEX KEY: 0001714828 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40187 FILM NUMBER: 23538733 MAIL ADDRESS: STREET 1: C/O CONATUS PHARMACEUTICALS INC. STREET 2: 16745 WEST BERNARDO DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92127 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prometheus Biosciences, Inc. CENTRAL INDEX KEY: 0001718852 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 814282653 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 422-4300 MAIL ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Precision IBD, Inc. DATE OF NAME CHANGE: 20171004 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-17 0 0001718852 Prometheus Biosciences, Inc. RXDX 0001714828 Marshall Keith W C/O PROMETHEUS BIOSCIENCES, INC. 3050 SCIENCE PARK ROAD SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2023-01-17 4 M 0 5000 3.70 A 14811 D Common Stock 2023-01-17 4 S 0 5000 119.00 D 9811 D Stock Option (Right to Buy) 3.70 2023-01-17 4 M 0 5000 0.00 D 2030-12-17 Common Stock 5000 118040 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date. /s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall 2023-01-19